Regencell Bioscience Holdings (RGC) is down about 3% today as investors re-focus on supply and dilution risk after the company filed an at-the-market (ATM) offering program for up to $500 million in ordinary shares. The prospectus supplement highlights that selling stock under the ATM would be dilutive to existing holders, which can pressure price on down days even if the company hasn’t disclosed a specific draw amount for the session. (sec.gov)

RGC has shown extreme volatility and thin, headline-sensitive trading, so the presence of an ATM can change the way momentum traders and market makers manage risk: rallies can be met with fears of incremental supply, while dips can accelerate as liquidity thins. Recent trading action has also featured unusual, fast moves around volatility events, reinforcing that flows and market-structure dynamics can dominate day-to-day price action. (tipranks.com)

Key near-term tells include (1) any new SEC updates that clarify ATM usage, (2) volume spikes that suggest active distribution, and (3) any company communication that shifts attention back to operations rather than financing mechanics. Separately, RGC previously disclosed that directors and employees with stock options extended lock-up commitments through April 20, 2027, which can affect perceived float and amplify price swings when incremental supply is feared from other sources. (stocktitan.net)